Limit on lab-grown human embryos dropped by stem-cell body
By Nidhi Subbaraman,
Nature
| 05. 26. 2021
The International Society for Stem Cell Research relaxed the famous 14-day rule on culturing human embryos in its latest research guidelines.
The international body representing stem-cell scientists has torn up a decades-old limit on the length of time that scientists should grow human embryos in the lab, giving more leeway to researchers who are studying human development and disease.
Previously, the International Society for Stem Cell Research (ISSCR) recommended that scientists culture human embryos for no more than two weeks after fertilization. But on 26 May, the society said it was relaxing this famous limit, known as the ‘14-day rule’. Rather than replace or extend the limit, the ISSCR now suggests that studies proposing to grow human embryos beyond the two-week mark be considered on a case-by-case basis, and be subjected to several phases of review to determine at what point the experiments must be stopped.
The ISSCR made this change and others to its guidelines for biomedical research in response to rapid advances in the field, including the ability to create embryo-like structures from human stem cells. In addition to relaxing the ‘14-day rule’, for instance, the group advises against editing genes in human embryos until the safety of genome...
Related Articles
By Ashley Smart , Undark | 07.24.2026
As Edward Donnell Ivy remembers it, many of the sickle cell episodes he endured in his 20s were akin to headaches or colds: They hurt, but he could still get up and go.
Every so often, though, he would be gripped...
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...